New News information at Drug Development Technology New and updated information from News listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New News information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics http://www.drugdevelopment-technology.com/news/newsdeals-this-week-nabriva-therapeutics-lifemine-therapeutics-aldeyra-therapeutics-5930760 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-nabriva-therapeutics-lifemine-therapeutics-aldeyra-therapeutics-5930760 Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock. Thu, 21 Sep 2017 23:00:00 GMT Audentes commences dosing in Phase I/II trial for myotubular myopathy http://www.drugdevelopment-technology.com/news/newsaudentes-commences-dosing-in-phase-iii-trial-for-myotubular-myopathy-5931919 http://www.drugdevelopment-technology.com/news/newsaudentes-commences-dosing-in-phase-iii-trial-for-myotubular-myopathy-5931919 US-based biotechnology firm Audentes Therapeutics has commenced patient dosing in the Phase I/II ASPIRO clinical trial of its product candidate AT132 to treat X-linked myotubular myopathy (XLMTM). Thu, 21 Sep 2017 23:00:00 GMT Shire reports positive data from Phase III trial of Intuniv for ADHD http://www.drugdevelopment-technology.com/news/newsshire-reports-positive-data-from-phase-iii-trial-of-intuniv-for-adhd-5932144 http://www.drugdevelopment-technology.com/news/newsshire-reports-positive-data-from-phase-iii-trial-of-intuniv-for-adhd-5932144 Irish biotechnology firm Shire and its Japanese partner Shionogi have reported positive top-line results from a Phase III clinical trial of Intuniv (guanfacine hydrochloride prolonged release) in adults with attention deficit hyperactivity disorder (… Thu, 21 Sep 2017 23:00:00 GMT AgeneBio to study AGB101 in Phase III trial to treat MCI due to AD http://www.drugdevelopment-technology.com/news/newsagenebio-to-study-agb101-in-phase-iii-trial-to-treat-mci-due-to-ad-5930652 http://www.drugdevelopment-technology.com/news/newsagenebio-to-study-agb101-in-phase-iii-trial-to-treat-mci-due-to-ad-5930652 US-based pharmaceutical firm AgeneBio is set to investigate its therapeutic agent AGB101 in a Phase III clinical trial (HOPE4MCI) for the treatment of mild cognitive impairment due to Alzheimer’s disease (MCI due to AD). Wed, 20 Sep 2017 23:00:00 GMT Parker Institute begins dosing in Phase Ib/II combination trial for pancreatic cancer http://www.drugdevelopment-technology.com/news/newsparker-institute-begins-dosing-in-phase-ibii-combination-trial-for-pancreatic-cancer-5930999 http://www.drugdevelopment-technology.com/news/newsparker-institute-begins-dosing-in-phase-ibii-combination-trial-for-pancreatic-cancer-5930999 The Parker Institute for Cancer Immunotherapy and Cancer Research Institute in the US have started dosing patients in a Phase Ib/II clinical trial to investigate the combination of standard chemotherapy and immunotherapy for the treatment of pancreat… Wed, 20 Sep 2017 23:00:00 GMT Transgene starts dosing in Phase Ib/II combination trial for HPV-positive cancers http://www.drugdevelopment-technology.com/news/newstransgene-starts-dosing-in-phase-ibii-combination-trial-for-hpv-positive-cancers-5930643 http://www.drugdevelopment-technology.com/news/newstransgene-starts-dosing-in-phase-ibii-combination-trial-for-hpv-positive-cancers-5930643 Transgene has started dosing patients in a Phase Ib/II clinical trial of TG4001 in combination with avelumab to treat human papillomavirus type 16 positive (HPV-16+) recurrent or metastatic cancers. Wed, 20 Sep 2017 23:00:00 GMT Cytokinetics begins dosing omecamtiv mecarbil in Phase III cardiovascular trial http://www.drugdevelopment-technology.com/news/newscytokinetics-begins-dosing-omecamtiv-mecarbil-in-phase-iii-cardiovascular-trial-5929911 http://www.drugdevelopment-technology.com/news/newscytokinetics-begins-dosing-omecamtiv-mecarbil-in-phase-iii-cardiovascular-trial-5929911 Cytokinetics has begun dosing patients in Japan in a Phase III cardiovascular outcomes clinical trial (GALACTIC-HF) of omecamtiv mecarbil as a potential heart failure treatment. Tue, 19 Sep 2017 23:00:00 GMT Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL http://www.drugdevelopment-technology.com/news/newsformula-pharma-initiates-phase-iiia-trial-of-allogeneic-cik-cells-for-all-5929899 http://www.drugdevelopment-technology.com/news/newsformula-pharma-initiates-phase-iiia-trial-of-allogeneic-cik-cells-for-all-5929899 US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL). Tue, 19 Sep 2017 23:00:00 GMT Janssen reports positive long-term Phase III data of Tremfya for plaque psoriasis http://www.drugdevelopment-technology.com/news/newsjanssen-reports-positive-long-term-phase-iii-data-of-tremfya-for-plaque-psoriasis-5930047 http://www.drugdevelopment-technology.com/news/newsjanssen-reports-positive-long-term-phase-iii-data-of-tremfya-for-plaque-psoriasis-5930047 Janssen Research & Development has reported new positive two-year results from the open-label extension of the Phase III VOYAGE 1 trial of Tremfya (Guselkumab) to treat moderate-to-severe plaque psoriasis. Tue, 19 Sep 2017 23:00:00 GMT Australian cancer centres launch personalised medicine trial for childhood cancers http://www.drugdevelopment-technology.com/news/newsaustralian-cancer-centres-launch-personalised-medicine-trial-for-childhood-cancers-5928482 http://www.drugdevelopment-technology.com/news/newsaustralian-cancer-centres-launch-personalised-medicine-trial-for-childhood-cancers-5928482 Cancer centres in Australia have launched a national clinical trial under the Zero Childhood Cancer programme to evaluate personalised medicine for childhood cancers. Mon, 18 Sep 2017 23:00:00 GMT Inovio launches Phase I/IIa trial for MERS infection in South Korea http://www.drugdevelopment-technology.com/news/newsinovio-launches-phase-iiia-trial-for-mers-infection-in-south-korea-5928765 http://www.drugdevelopment-technology.com/news/newsinovio-launches-phase-iiia-trial-for-mers-infection-in-south-korea-5928765 US-based immunotherapy firm Inovio Pharmaceuticals has launched a Phase I/IIa clinical trial of its vaccine candidate GLS-5300 to treat MERS (Middle East Respiratory Syndrome) infection in South Korea. Mon, 18 Sep 2017 23:00:00 GMT Sanofi and Regeneron report positive Phase III data from atopic dermatitis trial http://www.drugdevelopment-technology.com/news/newssanofi-and-regeneron-report-positive-phase-iii-data-from-atopic-dermatitis-trial-5928452 http://www.drugdevelopment-technology.com/news/newssanofi-and-regeneron-report-positive-phase-iii-data-from-atopic-dermatitis-trial-5928452 Sanofi and Regeneron Pharmaceuticals have reported positive results from the Phase III clinical trial (CAFÉ) of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis (AD). Mon, 18 Sep 2017 23:00:00 GMT TG Therapeutics commences enrolment for Phase III multiple sclerosis trials http://www.drugdevelopment-technology.com/news/newstg-therapeutics-commences-enrolment-for-phase-iii-multiple-sclerosis-trials-5927999 http://www.drugdevelopment-technology.com/news/newstg-therapeutics-commences-enrolment-for-phase-iii-multiple-sclerosis-trials-5927999 US-based biopharmaceutical firm TG Therapeutics has commenced enrolment for the Phase III ULTIMATE clinical programme of TG-1101 (ublituximab) to treat patients with relapsing multiple sclerosis (RMS). Sun, 17 Sep 2017 23:00:00 GMT Phrixus to study P-188 NF in Phase II trial to treat DMD http://www.drugdevelopment-technology.com/news/newsphrixus-to-study-p-188-nf-in-phase-ii-trial-to-treat-dmd-5927715 http://www.drugdevelopment-technology.com/news/newsphrixus-to-study-p-188-nf-in-phase-ii-trial-to-treat-dmd-5927715 US-based Phrixus Pharmaceuticals is set to conduct a Phase II clinical trial of Poloxamer 188 NF (P-188 NF) for the treatment of non-ambulatory patients with Duchenne muscular dystrophy (DMD). Sun, 17 Sep 2017 23:00:00 GMT Novo Nordisk’s Tresiba minimises hypoglycaemia rate in diabetes trial http://www.drugdevelopment-technology.com/news/newsnovo-nordisks-tresiba-minimises-hypoglycaemia-rate-in-diabetes-trial-5927723 http://www.drugdevelopment-technology.com/news/newsnovo-nordisks-tresiba-minimises-hypoglycaemia-rate-in-diabetes-trial-5927723 Denmark-based pharmaceutical firm Novo Nordisk has reported positive results from a clinical trial (DEVOTE) of Tresiba (insulin degludec) to treat patients with type 2 diabetes. Sun, 17 Sep 2017 23:00:00 GMT M&As this week: inviCRO, Inotek Pharmaceuticals Corporation http://www.drugdevelopment-technology.com/news/newsmas-this-week-invicro-inotek-pharmaceuticals-corporation-5925418 http://www.drugdevelopment-technology.com/news/newsmas-this-week-invicro-inotek-pharmaceuticals-corporation-5925418 inviCRO has completed the acquisition of UK-based translational research company Imanova. Thu, 14 Sep 2017 23:00:00 GMT Deals this week: Synthetic Biologics, Bayer, HitGen http://www.drugdevelopment-technology.com/news/newsdeals-this-week-synthetic-biologics-bayer-hitgen-5925416 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-synthetic-biologics-bayer-hitgen-5925416 Synthetic Biologics has raised $12m through the private placement of 120,000 series A preferred shares priced at $100 a share. Thu, 14 Sep 2017 23:00:00 GMT Tulane University reports favourable results from new malaria trial http://www.drugdevelopment-technology.com/news/newstulane-university-reports-favourable-results-from-new-malaria-trial-5926391 http://www.drugdevelopment-technology.com/news/newstulane-university-reports-favourable-results-from-new-malaria-trial-5926391 Tulane University in the US has reported positive results from a clinical trial of its new drug AQ-13, which is being developed for the treatment of malaria. Thu, 14 Sep 2017 23:00:00 GMT Pfizer and Astellas report positive Phase III data from prostate cancer trial http://www.drugdevelopment-technology.com/news/newspfizer-and-astellas-report-positive-phase-iii-data-from-prostate-cancer-trial-5926407 http://www.drugdevelopment-technology.com/news/newspfizer-and-astellas-report-positive-phase-iii-data-from-prostate-cancer-trial-5926407 Pfizer and Astellas Pharma have reported positive results from a Phase III clinical trial (PROSPER) of Xtandi (enzalutamide) in combination with androgen deprivation therapy (ADT) to treat patients with non-metastatic (M0) castration-resistant prosta… Thu, 14 Sep 2017 23:00:00 GMT Menarini and OBT conduct Phase I oncology trial of MEN1309 http://www.drugdevelopment-technology.com/news/newsmenarini-and-obt-conduct-phase-i-oncology-trial-of-men1309-5925621 http://www.drugdevelopment-technology.com/news/newsmenarini-and-obt-conduct-phase-i-oncology-trial-of-men1309-5925621 Italian pharmaceutical company Menarini Ricerche has partnered with UK-based biotechnology firm Oxford BioTherapeutics (OBT) to conduct a Phase I clinical trial of MEN1309 to treat patients with metastatic solid cancers and non-Hodgkin’s lymphoma (NH… Wed, 13 Sep 2017 23:00:00 GMT